Seelos Therapeutics to Participate in Two Upcoming Psychedelic Conferences
Seelos Therapeutics (Nasdaq: SEEL) announced participation in two key psychedelic conferences focusing on mental health treatments. The events, Jefferies Innovation in Mental Health Summit on September 22nd and Cantor Neurology and Psychiatry Conference on October 6th, will feature discussions about the clinical study of SLS-002, an intranasal racemic ketamine designed to treat suicidality in patients with Major Depressive Disorder. SLS-002 is noteworthy for being the only drug in its class currently in a registrational study targeting Acute Suicidal Ideation and Behavior.
- None.
- None.
- Seelos' SLS-002 is currently being developed specifically to treat the symptoms of suicidality associated with major depression
NEW YORK, Aug. 30, 2022 /PRNewswire/ -- Seelos Therapeutics, Inc. (Nasdaq: SEEL), a clinical-stage biopharmaceutical company focused on the development of therapies for central nervous system disorders and rare diseases, today announced that it will participate in two upcoming psychedelic conferences:
- Jefferies Innovation in Mental Health Summit, Psychedelics and New Emerging Treatments, September 22nd in New York City, NY
- Cantor Neurology and Psychiatry Conference, October 6th in San Francisco, CA
Raj Mehra, Ph.D., Chairman and CEO of Seelos, and senior management will participate in fireside chats, presentations and 1x1 meetings at these upcoming events to discuss the ongoing registrational, double-blind, placebo-controlled study of SLS-002 (intranasal racemic ketamine) for Acute Suicidal Ideation and Behavior (ASIB) in patients with Major Depressive Disorder (MDD).
"SLS-002 is currently being developed specifically to treat the symptoms of suicidality and is currently, we believe, the only drug in this class that is enrolling in a registrational clinical study to measure its effect on patients with acute suicidality in MDD. Suicides and suicide attempts claim far too many lives in the U.S. and globally and are devastating to loved ones. Still, there remains a dire need for a therapeutic labeled to treat the symptoms of suicidality," said Raj Mehra Ph.D., Chairman and CEO of Seelos. "We find it highly encouraging to see the level of interest and acceptance of the psychedelic class of drugs being studied to treat patients suffering with mental health issues and Seelos is proud to be at the forefront of this exciting new therapeutic class."
If you or a loved one are having thoughts of suicide, please seek immediate medical help, go to your nearest emergency room, or call the Suicide and Crisis Lifeline at 988 or 1-800-273-8255 (TALK).
SLS-002 is intranasal racemic ketamine with two investigational new drug applications for the treatment of Acute Suicidal Ideation and Behavior in Major Depressive Disorder or Post-Traumatic Stress Disorder. SLS-002 was originally derived from a Javelin Pharmaceuticals, Inc./Hospira, Inc. program with 16 clinical studies involving approximately 500 subjects. SLS-002 looks to address an unmet need for a therapy to treat suicidality in the U.S. Traditionally, anti-depressants have been used in this setting but many of the existing treatments are known to contribute to an increased risk of suicidal thoughts in some circumstances, and if they are effective, it often takes weeks for the full therapeutic effect to be manifested. The clinical development program for SLS-002 includes two parallel healthy volunteer studies (Phase I) and is being followed by pivotal registration studies after meeting with the FDA. Based on information gathered from the databases of the Agency for Healthcare Research and Quality, there were more than 1,000,000 visits to emergency rooms for suicide attempts in 2019 in the U.S. alone. Experimental studies suggest ketamine has the potential to be a rapid, effective treatment for depression and suicidality.
Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and advancement of novel therapeutics to address unmet medical needs for the benefit of patients with central nervous system (CNS) disorders and other rare diseases. The Company's robust portfolio includes several late-stage clinical assets targeting indications including Acute Suicidal Ideation and Behavior (ASIB) in Major Depressive Disorder (MDD) or Post-Traumatic Stress Disorder (PTSD), amyotrophic lateral sclerosis (ALS), spinocerebellar ataxia (SCA), Sanfilippo syndrome, Parkinson's disease, other psychiatric and movement disorders plus orphan diseases.
For more information, please visit our website: http://seelostherapeutics.com, the content of which is not incorporated herein by reference.
Statements made in this press release, which are not historical in nature, constitute forward-looking statements for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. These statements include, among others, those regarding Seelos' belief that SLS-002 is the only drug enrolling in a registrational clinical study to measure its effects on patients with ASIB in MDD. These statements are based on Seelos' current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Risks associated to Seelos' business include, but are not limited to, the risk of not successfully executing its preclinical and clinical studies, and not gaining marketing approvals for its product candidates, the risk that prior clinical results may not be replicated in future studies and trials, the risks that clinical study results may not meet any or all endpoints of a clinical study and that any data generated from such studies may not support a regulatory submission or approval, the risks associated with the implementation of a new business strategy, the risks related to raising capital to fund its development plans and ongoing operations, risks related to Seelos' current stock price, risks related to the global impact of COVID-19, as well as other factors expressed in Seelos' periodic filings with the U.S. Securities and Exchange Commission, including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, even if subsequently made available by us on our website or otherwise. We do not undertake any obligation to update, amend or clarify these forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws.
Contact Information:
Anthony Marciano
Chief Communications Officer
Seelos Therapeutics, Inc. (Nasdaq: SEEL)
300 Park Avenue, 2nd Floor
New York, NY 10022
(646) 293-2136
anthony.marciano@seelostx.com
https://seelostherapeutics.com/
https://twitter.com/seelostx
https://www.linkedin.com/company/seelos
Mike Moyer
Managing Director
LifeSci Advisors, LLC
250 West 55th St., Suite 3401
New York, NY 10019
(617) 308-4306
mmoyer@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/seelos-therapeutics-to-participate-in-two-upcoming-psychedelic-conferences-301614155.html
SOURCE Seelos Therapeutics, Inc.
FAQ
What is SLS-002 and its significance for suicidality in major depression?
When are the conferences Seelos Therapeutics is participating in?
What is the primary focus of the discussions at the upcoming conferences?
Is SLS-002 the only drug in a registrational study for suicidality?
What is the importance of SLS-002 according to Seelos Therapeutics' CEO?
